Search results for "Digestive System"

showing 10 items of 1747 documents

FibroScan Identifies Patients With Nonalcoholic Fatty Liver Disease and Cardiovascular Damage

2020

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are closely associated, and liver fibrosis has been related to macrovascular complications. We examined whether liver fibrosis, diagnosed by FibroScan® , correlates with chronic vascular complications in a cohort of T2DM. METHODS: We recruited 394 outpatients with T2DM attending five Italian diabetes centres who underwent liver ultrasonography (US), FibroScan® and extensive evaluation of macrovascular and microvascular diabetic complications. RESULTS: Steatosis by US was present in 89%. Almost all patients (96%) were on hypoglycaemic drugs, 58% had at least one chronic vascular complication,…

Liver CirrhosisNonalcoholic steatohepatitismedicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicine.diseaseFibrosisGastroenterologydigestive system diseasesNASH FIBROSCAN CARDIOVASCULARLiverNon-alcoholic Fatty Liver DiseaseFibrosiscardiovascular diseaseInternal medicineNAFLDNonalcoholic fatty liver diseasemedicineElasticity Imaging TechniquesHumanstype 2 diabetesbusinessliver stiffness measurementmicrovascular complication
researchProduct

2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines

2012

Hepatitis C virus (HCV) is the leading cause of liver transplantation in Europe and is associated with an increased risk of hepatocellular carcinoma (HCC). Because of the chronic nature of the disease, estimates suggest that the burden on healthcare will increase dramatically for this entity. Clinical care of patients with HCV-related liver disease has advanced considerably in the last two decades, thanks to increasing knowledge about the mechanisms of the disease, development of diagnostic procedures, and advances in therapeutic and preventive approaches. HCV RNA testing, HCV genotyping and staging of liver disease are essential for the diagnosis and the management of HCV therapy. Furtherm…

Liver CirrhosisOncologymedicine.medical_specialtyGenotypemedicine.medical_treatmentHepatitis C virusHepacivirusDiseaseLiver transplantationmedicine.disease_causeAntiviral AgentsPolyethylene GlycolsLiver diseasechemistry.chemical_compoundPegylated interferonInternal medicineRibavirinmedicineHumansHepatologybusiness.industryRibavirinInterferon-alphavirus diseasesStandard of CareHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseasesClinical PracticechemistryHepatocellular carcinomaPractice Guidelines as TopicImmunologyRNA ViralDrug Therapy Combinationbusinessmedicine.drugLiver International
researchProduct

StellaTUM: current consensus and discussion on pancreatic stellate cell research

2011

The field of pancreatic stellate cell (PSC) biology is very young, as the essential in-vitro tools to study these cells (ie, methods to isolate and culture PSC) were only developed as recently as in 1998. Nonetheless, there has been an exponential increase in research output in this field over the past decade, with numerous research groups around the world focusing their energies into elucidating the biology and function of these cells. It is now well established that PSC are responsible for producing the stromal reaction (fibrosis) of two major diseases of the pancreas—chronic pancreatitis and pancreatic cancer. Despite exponentially increasing data, the methods for studying PSC remain var…

Liver CirrhosisPathologycell migrationpancreatic cancerCellpancreatitisPancreatic stellate cellLeading Articlehepatic surgerycell biologymolecular biologyhepatic fibrosis1506pancreaspancreatic surgerysignallinghepatic stellate cellalcoholPancreatic Stellate CellsGastroenterologypancreatic functionddc:medicine.anatomical_structurePancreaspancreatic fibrosissignal transductionstellate cellsmedicine.medical_specialtyStromal cellacute pancreatitisextracellular matrixadjuvant treatmentAbdominal surgerycancer geneticsliverpancreatic enzymesdigestive systemchronic pancreatitisstem cellsPancreatitis ChronicPancreatic cancermedicinecancerHumansRegenerationpancreatic physiologyendoscopyProgenitor cellmarkeradenocarcinomaHelicobacter pyloribusiness.industryfibrosisPancreatic Diseasesmedicine.diseaseexperimental pancreatitisLiver RegenerationPancreatic Neoplasmspancreatic pathologyconsensusCancer cellgene expressionHepatic stellate cellbusinesspancreatic diseaseGut
researchProduct

Detection of hepatitis C virus replication in ovarian metastases of a patient with hepatocellular carcinoma.

1994

Hepatocellular carcinoma is one of the most common human cancers with an annual incidence of about 1,000,000 cases worldwide. Although hepatocellular carcinoma is predominant in hepatitis B virus endemic areas, it has also become a major problem in Europe, Japan and North America in close association with the increasing incidence of hepatitis C virus infection. The pathogenetic role of hepatitis C virus infection in the development of HBsAg-negative hepatocellular carcinoma needs to be clarified. In this paper the case of a 66-year-old HBsAg-negative and anti-HCV positive female who developed hepatocellular carcinoma in a cirrhotic liver is reported. After 1 year of follow up, urgent laparo…

Liver CirrhosisPathologymedicine.medical_specialtyCarcinoma HepatocellularHepatitis C virusHepacivirusOvaryHepacivirusmedicine.disease_causeVirus ReplicationGastroenterologyVirusMetastasisFlaviviridaeInternal medicinemedicineHumansAgedHepatitis B virusOvarian NeoplasmsHepatitis B Surface AntigensHepatologybiologyIncidenceLiver Neoplasmsmedicine.diseasebiology.organism_classificationdigestive system diseasesmedicine.anatomical_structureHepatocellular carcinomaRNA ViralFemaleTomography X-Ray ComputedJournal of hepatology
researchProduct

Spike-in SILAC proteomic approach reveals the vitronectin as an early molecular signature of liver fibrosis in hepatitis C infections with hepatic ir…

2014

Hepatitis C virus (HCV)-induced iron overload has been shown to promote liver fibrosis, steatosis, and hepatocellular carcinoma. The zonal-restricted histological distribution of pathological iron deposits has hampered the attempt to perform large-scale in vivo molecular investigations on the comorbidity between iron and HCV. Diagnostic and prognostic markers are not yet available to assess iron overload-induced liver fibrogenesis and progression in HCV infections. Here, by means of Spike-in SILAC proteomic approach, we first unveiled a specific membrane protein expression signature of HCV cell cultures in the presence of iron overload. Computational analysis of proteomic dataset highlighte…

Liver CirrhosisProteomicshepatitis C virusMaleMESH: Isotope LabelingHSCmedicine.disease_causeBiochemistry0302 clinical medicineFibrosisMESH: Up-RegulationMembrane Proteinhepatic stellate cellliver fibrosishepatic iron overload0303 health sciencesbiologyMESH: ProteomicsMedicine (all)hepatocellular carcinomaBiomedicine; hepatitis c infection; liver fibrosis; hepatic iron overload; vitronectinHepatitis C[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM]Hepatitis CUp-Regulation3. Good healthcell culture-derived HCVIsotope Labeling030220 oncology & carcinogenesisHepatocellular carcinomaBiomedicine; Hepatic iron overload; Hepatitis C infection; Liver fibrosis; Vitronectin; Biomarkers; Cell Line; Hepatitis C; Humans; Iron Overload; Isotope Labeling; Liver Cirrhosis; Male; Membrane Proteins; Proteomics; Up-Regulation; Vitronectin; Molecular Biology; Biochemistry; Medicine (all)HCV[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyBiomarker (medicine)VitronectinMESH: Membrane ProteinsMESH: Liver CirrhosisHumanIron OverloadLiver CirrhosiHepatitis C virusvitronectinhepatitis c infectionCell LineMESH: Iron Overload03 medical and health sciencesmedicineHumans[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMolecular Biology030304 developmental biologyMESH: Hepatitis CMESH: HumansMESH: Biological MarkersMembrane ProteinsLiver fibrosiProteomicBiomarkermedicine.diseaseMESH: VitronectinMESH: Maledigestive system diseasesMESH: Cell LineBiomedicineBiomedicine / Abbreviations: HCCHCVccImmunologyCancer researchHepatic stellate cellbiology.proteinSteatosisBiomarkersPROTEOMICS
researchProduct

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.

2014

Introduction: On-treatment HCV RNA measurements are crucial for the prediction of a sustained virological response (SVR) and to determine treatment futility during protease inhibitor-based triple therapies. In patients with advanced liver disease an accurate risk/benefit calculation based on reliable HCV RNA results can reduce the number of adverse events. However, the different available HCV RNA assays vary in their diagnostic performance. Aim: To investigate the clinical relevance of concordant and discordant results of two HCV RNA assays during triple therapy with boceprevir and telaprevir in patients with advanced liver fibrosis/cirrhosis. Methods: We collected on-treatment samples of 1…

Liver CirrhosisViral DiseasesCirrhosisGastroenterology and hepatologyHepaciviruslcsh:MedicineHepacivirusmedicine.disease_causeGastroenterologyTelaprevirHepatitisLiver diseasechemistry.chemical_compoundMedicinelcsh:ScienceMultidisciplinarybiologyvirus diseasesHepatitis CHepatitis CClinical Laboratory SciencesEuropeClinical LaboratoriesInfectious hepatitisInfectious DiseasesTreatment OutcomeAnti-Retroviral AgentsHCVRNA ViralOligopeptidesmedicine.drugResearch Articlemedicine.medical_specialtyGenotypeProlineHepatitis C virusDiagnostic MedicinePredictive Value of TestsBoceprevirInternal medicineHumansProtease InhibitorsViremiaddc:610Liver diseasesMedicine and health sciencesbusiness.industryClinical Laboratory Techniqueslcsh:RRNAReproducibility of Resultsmedicine.diseasebiology.organism_classificationdigestive system diseaseschemistryImmunologylcsh:Qbusiness
researchProduct

Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice.

2020

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) prevalence has increased in the past two decades, resulting in a significant but under-recognised public health burden. This impacts the prevalence of advanced fibrosis, end-stage liver disease and associated extrahepatic manifestations. To understand the challenges in recognising patients with advanced fibrosis due to NASH and develop a standardised approach to screen these patients, the authors of this document provided their opinions and expertise from practice and published evidence to identify key challenges and current approaches for diagnosing NASH. The severity of liver fibrosis due to NASH is the main …

Liver Cirrhosismedicine.medical_specialtyBest practicePsychological interventionMEDLINEDiseasedigestive systemRisk Assessment03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasemedicineHumansMass ScreeningIntensive care medicinebusiness.industryPublic healthGastroenterologymedicine.diseaseAdvanced fibrosis Best practice Identification NAFLD NASHdigestive system diseasesEarly Diagnosis030220 oncology & carcinogenesisPractice Guidelines as TopicDisease Progression030211 gastroenterology & hepatologyIdentification (biology)businessAlgorithmsJournal of gastrointestinal and liver diseases : JGLD
researchProduct

Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta -Analysis

2020

Background & Aims:\ud Biopsy-confirmed liver fibrosis is a prognostic factor for patients with nonalcoholic fatty liver disease (NAFLD). We performed a systematic review to quantify the prognostic value of fibrosis stage in patients with NAFLD and the subgroup of patients with nonalcoholic steatohepatitis (NASH) and to assess the evidence that change in fibrosis stage is a surrogate endpoint.\ud \ud Methods:\ud We searched the MEDLINE, Embase, Cochrane Library, and trial registry databases through August 2018 for prospective or retrospective cohort studies of liver-related clinical events and outcomes in adults with NAFLD or NASH. We collected data on mortality (all cause and liver rela…

Liver Cirrhosismedicine.medical_specialtyBiopsyRisk AssessmentSeverity of Illness IndexLiver diseaseFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineRisk of mortalityHumansHepatologybusiness.industrySurrogate endpointGastroenterologyKlinisk medicinRetrospective cohort studyConfounding Factors Epidemiologicmedicine.diseasePrognosisdigestive system diseasesLiverRelative riskMeta-analysisQuality of LifeClinical Medicinebusiness
researchProduct

Computed tomographic imaging of hepatocellular carcinoma

2004

The ability of x-ray computed tomography (CT) to detect and characterize liver lesions has been one of the most studied issues in radiology during the past 20 years. Technological advances, combined with increased knowledge about the pathophysiological characteristics of these tumors, have dramatically increased the ability to detect and characterize large hepatocellular carcinomas (HCCs). Nonetheless, detection and characterization of early and small HCC lesions remains a difficult task. We review the imaging appearances of HCC on CT and discuss the sensitivity and specificity of computed tomographic imaging in screening patients with cirrhosis for HCC.

Liver Cirrhosismedicine.medical_specialtyCarcinoma HepatocellularCirrhosisHepatologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsGastroenterologyComputed tomographymedicine.diseaseSensitivity and Specificitydigestive system diseasesComputed tomographicX ray computedHepatocellular carcinomaCarcinomamedicineHumansTomographyRadiologyTomography X-Ray ComputedbusinessneoplasmsGastroenterology
researchProduct

Congenital Cystic Lesions of the Bile Ducts: Imaging-Based Diagnosis

2020

Congenital cystic lesions of the bile ducts represent a spectrum of liver and biliary system lesions, resulting from abnormal embryologic development of the ductal plate. These disorders include Caroli disease, choledochal cysts, autosomal dominant polycystic liver disease, congenital hepatic fibrosis, and biliary hamartomas. Each disorder carries a peculiar clinical presentation, prognosis, and risk of complications. Knowledge of radiological findings of fibropolycystic liver diseases is crucial for their appropriate detection and for differential diagnosis with other similar hepatic cystic lesions, in order to avoid relevant misdiagnosis. The aim of this review is to provide an illustrati…

Liver Cirrhosismedicine.medical_specialtyCaroli diseaseDigestive System DiseasesHamartomaCystic lesions030218 nuclear medicine & medical imagingDiagnosis Differential03 medical and health sciencesCystic lesion0302 clinical medicineMedicineHumansRadiology Nuclear Medicine and imagingCholedochal cystsFibropolycystic liver diseasemedicine.diagnostic_testbusiness.industryCystsPolycystic liver diseaseLiver DiseasesUltrasoundGenetic Diseases InbornMagnetic resonance imagingmedicine.diseaseCaroli DiseaseLiver030220 oncology & carcinogenesisCongenital hepatic fibrosisRadiologyDifferential diagnosisbusinessSettore MED/36 - Diagnostica Per Immagini E Radioterapia
researchProduct